News & Updates

Massage therapy shows promise for chemo-induced pain

15 Nov 2022

Massage therapy appears to ease chemotherapy-induced peripheral neuropathy (CIPN) regardless of whether it is directed at the site of pain or not, reports a recent study.

Massage therapy shows promise for chemo-induced pain

15 Nov 2022

Air pollution may cause lung cancer among never smokers

15 Nov 2022 by

Data presented at the recent European Society for Medical Oncology (ESMO) Congress 2022 reveals a new mechanism by which very small pollutant particles in the air may cause lung cancer in people who have never smoked. The newly discovered pathway paves the way for the development of new prevention strategies and therapies, say the study authors. [Ann Oncol 2022;33(Suppl 7):S808–S869]

Air pollution may cause lung cancer among never smokers

15 Nov 2022

Original New Drug Application Approvals by US FDA (01 - 15 November 2022)

15 Nov 2022

New drug applications approved by US FDA as of 01 - 15 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 November 2022)

15 Nov 2022

Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC

14 Nov 2022 by

In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC

14 Nov 2022

HKU programme offers free comprehensive genomic profiling tests to NSCLC patients

14 Nov 2022 by

The University of Hong Kong (HKU) has launched a precision oncology programme in partnership with public and private stakeholders to provide free comprehensive genomic profiling tests to 1,800 eligible patients with stage IV non-small-cell lung cancer (NSCLC) in Hong Kong. Initial data from the programme revealed less common mutations amenable to treatment with targeted therapies in a sizeable proportion of patients.

HKU programme offers free comprehensive genomic profiling tests to NSCLC patients

14 Nov 2022

Prophylactic gastrostomy improves outcomes in head and neck cancer

13 Nov 2022

Prophylactic percutaneous endoscopic gastrostomy (pPEG) can enhance nutrition outcomes, reduce treatment delay, and maintain quality of life (QoL) in patients with head and neck cancer (HNC), suggests a recent study.

Prophylactic gastrostomy improves outcomes in head and neck cancer

13 Nov 2022

KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment

11 Nov 2022 by

An extended 4.5-year follow-up of the phase III KEYNOTE-240 trial showed that pembrolizumab continued to provide clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), with a manageable safety profile, vs placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC).

KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment

11 Nov 2022

Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer

10 Nov 2022

Among prostate cancer patients on androgen deprivation therapy (ADT), a small prostate and higher reductions in testosterone levels appear to aggravate storage symptoms, a recent study has found.